Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review |
| |
| Affiliation: | 1. Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;2. Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA;3. Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA;4. Clinic of Internal Medicine, University Hospital Ostrava, Ostrava, Czech Republic;5. Gastroenterology Unit, Pancreas Center, University of Verona, Verona, Italy;6. Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan;7. Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan;8. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan;9. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;10. Department of Gastroenterology, San Carlo Hospital, Potenza, Italy;11. Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden;12. Department for Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden;13. CLINTEC, Karolinska Institute, Stockholm, Sweden;14. Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden;1. Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States;2. Division of Gastroenterology and Hepatology, John H. Stroger Cook County Hospital, Chicago, IL, United States;3. Department of Gastroenterology, BIDMC, Boston, United States;4. Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, United States;5. Division of Gastroenterology and Hepatology, Fox Chase Cancer Center, Philadelphia, United States;6. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, United States;1. Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23562 Luebeck, Germany;2. Department of Neuroradiology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23562 Luebeck, Germany;3. Department of Radiology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23562 Luebeck, Germany;4. Department of General Surgery, Bogomolets National Medical Unoversity, Kiev, Ukraine;1. Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;4. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;5. Evolution of Cancer, Leukemia and Immunity Post Stem Cell Transplant (ECLIPSE), The University of Texas MD Anderson Cancer Center, Houston, TX, USA;1. Department of Gastrointestinal Surgery, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey;2. Department of General Surgery, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey;3. Department of Medical Biochemistry, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey;1. Department of Pathology, Jeju National University Hospital, Jeju-si, South Korea;2. Department of Pathology and Molecular Diagnostic Laboratory, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea;1. Department of Surgery, Kansai Medical University, 2-5-1 Shin-machi, Hirakata-city, Osaka, 573-1010, Japan;2. Department of Pathology and Clinical Laboratory, Kansai Medical University, 2-5-1 Shin-machi, Hirakata-city, Osaka, 573-1010, Japan;3. Department of Surgery, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan |
| |
| Abstract: | BackgroundChronic pancreatitis is a known risk factor of pancreatic cancer (PDAC). A similar association has been suggested but not demonstrated for autoimmune pancreatitis (AIP).ObjectiveThe aim of our study was to identify and analyse all published cases of AIP and PDAC co-occurrence, focusing on the interval between the diagnoses and the cancer site within the pancreas.MethodsRelevant studies were identified through automatic searches of the MEDLINE, EMBASE, Scopus, and Web of Science databases, and supplemented by manual checks of reference lists in all retrieved articles. Missing/unpublished data were obtained from the authors of relevant publications in the form of pre-prepared questionnaires.ResultsA total of 45 cases of PDAC in AIP patients were identified, of which 12 were excluded from the analysis due to suspicions of duplicity or lack of sufficient data. Thirty-one patients (94%) had type 1 AIP. Synchronous occurrence of PDAC and AIP was reported in 11 patients (33%), metachronous in 22 patients (67%). In the metachronous group, the median period between diagnoses was 66.5 months (2–186) and a majority of cancers (86%) occurred more than two years after AIP diagnosis. In most patients (70%), the cancer originated in the part of the pancreas affected by AIP.ConclusionsIn the literature, there are reports on numerous cases of PDAC in AIP patients. PDAC is more frequent in AIP type 1 patients, typically metachronous in character, and generally found in the part of the pancreas affected by AIP. |
| |
| Keywords: | Autoimmune pancreatitis Chronic pancreatitis Immunoglobulin G4-Related disease Malignancy Pancreatic cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
